BioSpace News Archive

Palatin Technologies, Inc. (NYSE American: PTN), announced a presentation of the positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists.

Daxor Corporation announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022.

Aptevo Therapeutics Inc. today announced that founding chairman of the board, Fuad El-Hibri, has announced his retirement effective April 1, 2022. The Company also announced that long-time board member and vice chairman John E. Niederhuber, M.D., will assume the chairmanship, effective April 1, 2022.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m. ET.

China Jo-Jo Drugstores, Inc., a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products, and healthcare provider in China, announced its financial results for the first half of fiscal year 2022 ended September 30, 2021.

10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the expansion of its 10x Certified Service Provider (CSP) Network to include three leading clinical research organizations (CROs).

Medscape Education will host Hematologic Malignancies Demystified, a complimentary virtual conference that will take place on January 29 and February 5.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its Dental and Spine businesses into a standalone, publicly traded company, ZimVie.

Breaking research published today in AACC’s Clinical Chemistry journal shows that a new test can measure the amount of DNA damage in sperm with greater accuracy than current tests.

Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched PFAS Exposure™ in the United States, the first direct to consumer at-home test to determine levels of PFAS in a person’s blood and measure 47 of the PFAS “forever chemical” compounds.